UCSF home page About UCSF UCSF Medical Center
UCSF home page | About UCSF | UCSF Medical Center

Skip to TransPortal content

Decrease the text sizeRestore original text sizeIncrease the text size Enlarge Text
Click to increase the text size. Restore Text
Click to restore original text size. Reduce Text
Click to decrease the text size.
Transporter Database banner  
Decrease the text size | Restore text size | Increase the text size
 Text Sizer image
Home About and More Information Transporter Data Index
Search:  
 

Maraviroc

Substrate Information
Inhibitor Information
Clinical Drug-drug Interactions

In Vitro Substrates

* denotes drugs that can potentially be used for in vivo (clinical) studies of the designated transporter
Transporter Synonyms Km (μM) Cell System Reference
SLCO1B1 OATP1B1, OATP-C, OATP2, LST-1 33.9 OATP1B1-expressing oocytes Siccardi, 2010

Back to top

In Vitro Inhibitors

* denotes drugs that can potentially be used for in vivo (clinical) studies of the designated transporter
Transporter Synonyms Inhibitor IC50 (μM) Ki (μM) Substrate used Cell System Reference
SLC47A1 MATE1 Maraviroc 17.3 4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) HEK293-MATE1 Wittwer, 2013
SLC47A2 MATE2K Maraviroc 297 4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) HEK293-MATE2K Wittwer, 2013
ABCC2 MRP2, cMOAT Maraviroc >133 Estradiol-17beta-glucuronide Sf9 cell membrane vesicles Morgan, 2013
ABCC3 MRP3 Maraviroc >133 Estradiol-17beta-glucuronide Sf9 cell membrane vesicles Morgan, 2013
ABCC4 MRP4 Maraviroc >133 Estradiol-17beta-glucuronide Sf9 cell membrane vesicles Morgan, 2013
ABCB11 BSEP Maraviroc 110 Taurocholate Sf9 cell membrane vesicles Morgan, 2013

Back to top

Clinical Drug-Drug Interactions

No drug-drug interaction information.


Back to top

Contact us | Glossary

Blue banner